ZOLEDRONIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZOLEDRONIC (ZOLEDRONIC).
Inhibits osteoclast-mediated bone resorption via binding to hydroxyapatite and inhibiting farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and inducing osteoclast apoptosis.
| Metabolism | Zoledronic acid is not metabolized in humans and is eliminated unchanged primarily by the kidneys via glomerular filtration and tubular secretion. |
| Excretion | Zoledronic acid is excreted primarily unchanged by the kidneys via glomerular filtration and tubular secretion. Approximately 39 ± 16% of the administered dose is recovered in urine within 24 hours, with the remainder (up to 60%) retained in bone and slowly released over time. Fecal excretion is negligible (<1%). Renal clearance is dose-dependent and correlates with creatinine clearance. Dose adjustment is required for creatinine clearance <35 mL/min. |
| Half-life | The terminal elimination half-life of zoledronic acid is approximately 146 hours (range 44-196 hours) after a single intravenous dose. This long half-life reflects slow release from bone rather than systemic clearance. Despite the prolonged terminal phase, the clinical effect (suppression of bone resorption) persists for weeks to months. The initial distribution half-life is about 0.23 hours, and the intermediate half-life is about 1.75 hours. |
| Protein binding | Zoledronic acid is approximately 22-40% bound to plasma proteins, primarily to albumin. Binding is concentration-independent over the therapeutic range, but the exact binding proteins are not fully characterized. The unbound fraction (60-78%) is pharmacologically active. |
| Volume of Distribution | The volume of distribution (Vd) is 4.3-7.6 L/kg (approximately 300-530 L in a 70 kg adult). This large Vd indicates extensive distribution into bone, where it binds to hydroxyapatite, and also to soft tissues. The Vd increases with body weight. The rapid initial distribution phase reflects high affinity for bone (exposed hydroxyapatite surfaces). |
| Bioavailability | Zoledronic acid has negligible oral bioavailability (<0.5%) due to high polarity and poor intestinal absorption. Only intravenous administration is used clinically (IV infusion over at least 15 minutes for the 4 mg dose or 30-60 minutes for higher doses). Subcutaneous, intramuscular, and other routes are not recommended due to risk of local reactions and incomplete absorption. |
| Onset of Action | Intravenous: Suppression of bone resorption (measured by urinary N-telopeptide and serum CTX) is evident within 24-48 hours of a single 4 mg dose. The maximal decrease in bone turnover markers occurs by day 3-7. For hypercalcemia of malignancy, reduction in serum calcium begins within 2-4 days, with maximal effect by 7 days. No oral or other routes are available. |
| Duration of Action | Intravenous: The effect on bone resorption lasts for at least 11 days after a single 30-minute infusion of 4 mg, with sustained suppression of bone turnover markers for up to 4-6 weeks. In osteoporosis, repeat dosing every 12 months maintains effect. Clinical duration varies: for Paget's disease, remissions can last >2 years after a single dose. For hypercalcemia, normocalcemia is maintained for a median of 30 days. |
5 mg intravenously over at least 15 minutes once yearly for the treatment of osteoporosis, Paget's disease, or hypercalcemia of malignancy; for prevention of skeletal-related events in multiple myeloma or bone metastases: 4 mg intravenously over at least 15 minutes every 3-4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | For osteoporosis: not recommended if CrCl <35 mL/min. For Paget's disease or hypercalcemia: not recommended if CrCl <35 mL/min. For malignancy-related bone disease: if CrCl 30-60 mL/min, reduce dose to 3.5 mg; if CrCl <30 mL/min, not recommended. All doses should be administered only after correcting hypovolemia and monitoring serum creatinine. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment; not studied in severe hepatic impairment, use with caution. |
| Pediatric use | Not recommended for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required based on age alone; renal function should be assessed and dose adjusted accordingly as elderly patients are more likely to have decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZOLEDRONIC (ZOLEDRONIC).
| Breastfeeding | It is unknown if zoledronic acid is excreted in human breast milk. Due to potential for bone growth suppression and hypocalcemia in the infant, breastfeeding is not recommended during therapy and for at least 1 month after the last dose. M/P ratio is not available. |
| Teratogenic Risk | Zoledronic acid (a bisphosphonate) is FDA Pregnancy Category D. There is evidence of fetal harm based on animal studies and limited human data. In animal studies, it caused skeletal and visceral anomalies, reduced fetal weight, and increased fetal mortality. Use is contraindicated in pregnancy due to risk of fetal skeletal abnormalities and hypocalcemia. First trimester exposure carries the highest risk for skeletal teratogenicity. Second and third trimester exposure may cause fetal hypocalcemia and bone demineralization. |
■ FDA Black Box Warning
Zoledronic acid is not recommended for use in patients with severe renal impairment (CrCl <35 mL/min) due to increased risk of renal toxicity. Acute renal failure and renal impairment may occur after single or multiple doses, especially in patients with pre-existing renal disease or dehydration.
| Serious Effects |
["Hypocalcemia","Severe renal impairment (CrCl <35 mL/min)","Pregnancy (category D)","Breastfeeding","Hypersensitivity to zoledronic acid or any component of the formulation"]
| Precautions | ["Renal toxicity and acute renal failure, particularly in patients with impaired renal function or dehydration","Electrolyte disturbances (e.g., hypocalcemia, hypophosphatemia, hypomagnesemia)","Osteonecrosis of the jaw (ONJ), especially in cancer patients with dental risk factors","Atypical femur fractures with long-term use","Severe musculoskeletal pain","Bronchospasm in aspirin-sensitive asthmatic patients"] |
Loading safety data…
| Fetal Monitoring | Monitor serum calcium, phosphate, magnesium, and renal function before each dose. Assess for signs of hypocalcemia (tetany, paresthesias). In pregnancy, perform fetal ultrasound to assess skeletal development if exposure occurs. Monitor infant for hypocalcemia and bone abnormalities if born to exposed mother. |
| Fertility Effects | Zoledronic acid may impair fertility. In animal studies, it caused decreased fertility and implantation losses at high doses. In humans, long-term bisphosphonate use has been associated with delayed ovulation and possible reduced ovarian reserve, but data are limited. |